arrow
P

Panagiotis Malandrakis

National and Kapodistrian University of Athens
H指数:19
被引数:1,299

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience

IgM和waldenström巨球蛋白血症相关性神经病的治疗及长期血液学和神经学结局:单中心经验

2026-08-210
OAAI
A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias

家族性易感性在浆细胞异常中的前瞻性研究

2026-07-220
OA
Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PD-1抑制剂为基础方案在黑色素瘤患者中的疗效与安全性:一项随机对照试验的系统评价与Meta分析

2026-06-180
OA
The prognostic value of red blood cell distribution width in AL amyloidosis

AL淀粉样变性中红细胞分布宽度的预后价值

2026-05-160
PRE
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRFSerTGA leads to poor disease prognosis

探讨多发性骨髓瘤中的tRNA衍生小RNA:升高的3′U-tRFSerTGA导致不良疾病预后

2026-05-010
OAAI
Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients

真实世界中经批准的CAR T细胞疗法Ciltacabtagene autoleucel和Idecabtagene vicleucel在1272例复发/难治性多发性骨髓瘤患者中的应用经验

Cancers
IF4.4
2026-04-030
OAAI
Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study

患者、临床医生和研究者在多发性骨髓瘤重要结局上的优先事项:一项混合方法研究

2026-02-260
OAAI
Can Exercise Training Improve the Quality of Life and Physical Function in Multiple Myeloma Patients?: Discussing the Progression of the Training Stimulus

运动训练能否改善多发性骨髓瘤患者的生活质量和身体功能?:探讨训练刺激的进展

Sports
IF2.9
2026-02-040
OAAI
Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre

新诊断的华氏巨球蛋白血症患者在三级学术中心治疗后的临床结局

2026-01-220
PRE
Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma − a single center, retrospective imaging analysis on 119 patients

骨疾病负担不影响新诊断多发性骨髓瘤患者的总生存期——一项基于119例患者的单中心、回顾性影像学分析

2025-10-250
OAAI
Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies

下一代流式细胞术检测的循环肿瘤细胞作为无症状性单克隆丙种球蛋白病患者的新型预后生物标志物

2025-10-210
OA
Pomalidomide, cyclophosphamide and dexamethasone for relapsed/refractory multiple myeloma; a single-center experience

泊马利度胺、环磷酰胺和地塞米松用于复发/难治性多发性骨髓瘤;一项单中心经验

2025-08-050
OAAI
Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution

多发性骨髓瘤15年无进展生存的影响因素;单一机构真实世界数据

2025-07-180
OAAI
The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

高危细胞遗传学对复发/难治性多发性骨髓瘤患者疗效和结局的影响: 随机对照试验的系统评价和荟萃分析

Leukemia
IF13.4
2025-07-020
PRE